Monoclonal Gammopathy of Undetermined Significance (MGUS)

Introduction

March 2011

Welcome to Mayo Medical Laboratories' Hot Topics. These presentations provide short discussions of current topics and may be helpful to you in your practice.

Our presenter for this program is Dr. Jerry Katzmann, from the Division of Clinical Biochemistry and Immunology at Mayo Clinic. Dr. Katzmann will discuss laboratory testing for monoclonal gammopathy of undetermined significance (MGUS) and clinical implications of this diagnosis.

Today I want to talk about monoclonal gammopathy of undetermined significance — sometimes shortened to "mugus" or "M-gus." Years ago this abnormality was called benign monoclonal gammopathy (or BMG), but as we'll see, this was a misnomer.

MGUS is by far the most common monoclonal gammopathy that is identified in the laboratory. It is therefore important for laboratorians to understand this disorder.

Introduction

Next Slide >

 

Jump to section:

• Multiple Myeloma Slides
• Serum Protein Electrophoresis and Immunofixation Electrophoresis
• Monoclonal Serum Proteins¹: Newly Diagnosed Multiple Myeloma
• Monoclonal Gammopathies
• Monoclonal Gammopathies ("Other")
• Monoclonal Gammopathies
• Diagnostic Screening Panels: Sensitivity
• Monoclonal Gammopathies: Plasma Cell Proliferative Diseases
• Plasma Cell Proliferative Diseases: MGUS, SMM, MM2
• Probability of Progression⁴
• Prevalence of MGUS in Olmsted County, MN³
• MGUS Precedes Multiple Myeloma⁵
• Summary: Monoclonal Gammopathy Undetermined Significance (MGUS)
• Prognosis of MGUS: Size of M Spike and Risk of Progression to Malignancy⁶
• Prognosis of MGUS: Type of M spike and Absolute Risk of Progression to Malignancy⁶
• Population-Based Cohort Study: Impact of Free Light Chain on Progression⁷
• Multivariate Analysis of Prognostic Factors for Progression of MGUS⁷
• Risk Stratification Model Incorporating All 3 Predictive Factors⁷
• Diagnostic Screening Panels: Sensitivity
• MGUS: Summary
• References
• Questions?